Vertex Pharmaceuticals VRTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.22B+10.1% | $12B+8.9% | $11.72B+10.3% | $11.42B+10.5% | $11.1B+9.0% | ||
| $1.68B+8.4% | $1.65B+7.9% | $1.61B+9.1% | $1.59B+13.2% | $1.55B+15.9% | ||
| $10.54B+10.3% | $10.35B+9.1% | $10.11B+10.5% | $9.83B+10.0% | $9.55B+7.9% | ||
| 86.2%+0.2pp | 86.2%+0.1pp | 86.3%+0.2pp | 86.1%-0.3pp | 86%-0.8pp | ||
| $1.85B+21.9% | $1.75B+19.7% | $1.64B+12.9% | $1.57B+16.5% | $1.52B+22.6% | ||
| $7.54B-36.4% | $7.83B-30.4% | $7.73B-29.1% | $7.5B-29.9% | $11.84B+97.6% | ||
| $4.68B— | $4.17B— | —— | —— | —— | ||
| 38.3%— | 34.8%— | —— | —— | —— | ||
| $5.17B+1,821% | $4.64B+1,768% | $4.45B+1,614% | $4.37B+1,937% | -$300.2M-106% | ||
| $827.4M+20.1% | $690M-12.0% | $773.6M+4.6% | $736.4M+4.5% | $688.7M-7.9% | ||
| $4.34B— | $3.95B— | —— | —— | —— | ||
| 35.5%— | 32.9%— | —— | —— | —— | ||
| $16.85— | $15.32— | —— | —— | —— | ||
| $4.9B+1,247% | $4.38B+4,904% | $4.31B+8,596% | $4.24B+3,126% | -$426.9M-110% | ||
| 40.1%+43.9pp | 36.5%+35.7pp | 36.7%+37.2pp | 37.1%+38.5pp | -3.8%-46.9pp | ||
| $4.68B+844% | $4.17B+3,589% | $4.11B+1,619% | $4.04B+1,258% | -$629M-115% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Vertex Pharmaceuticals's revenue?
- Vertex Pharmaceuticals (VRTX) generated $12.2B in revenue over the trailing twelve months, up 10.1% year over year.
- Is Vertex Pharmaceuticals profitable?
- Vertex Pharmaceuticals reported $4.3B in net income over the trailing twelve months, a 35.5% net margin.
- What are Vertex Pharmaceuticals's profit margins?
- Gross margin is 86.2% and operating margin is 38.3%, with a 35.5% net margin.
- What is Vertex Pharmaceuticals's earnings per share?
- Vertex Pharmaceuticals's diluted EPS over the trailing twelve months is $16.85.
- Where does Vertex Pharmaceuticals's income statement data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
